Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 release regarding its partnership with TARA Mind. The correction notes that references to Veterans Exploring Treatment Solutions were removed from earlier paragraphs, while reaffirming the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership with TARA Mind is intended to support Phase 3 recruitment for Helus Pharma’s HLP003 program in major depressive disorder and expand outreach in veteran communities. HLP003 is a proprietary novel serotonergic agonist (NSA) currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on social media. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
This correction underscores the importance of accurate communication in clinical-stage pharmaceutical partnerships, particularly when involving veteran communities and government executive orders. The collaboration with TARA Mind remains focused on advancing mental health treatments and expanding clinical research participation, which could have significant implications for patients suffering from major depressive disorder and other mental health conditions.
